Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451679 | 0.81 | ALDH1A1 (0.52) | PDE10AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL448957 | 0.80 | CXCR3 (0.57) | CXCR3 | |
| SCHEMBL451493 | 0.75 | CXCR3 (0.50) | CXCR3MAPK1 | |
| SCHEMBL1484129 | 0.73 | MEN1 (0.66) | PDE10AMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL449371 | 0.73 | CXCR3 (0.57) | CXCR3 | |
| SCHEMBL451318 | 0.73 | CXCR3 (0.49) | CXCR3MAPK1 | |
| SCHEMBL452387 | 0.72 | HTR7 (0.59) | PDE10AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL452391 | 0.72 | CXCR3 (0.52) | PDE10AALDH1A1SMN1; SMN2CXCR3MAPK1 | |
| SCHEMBL451143 | 0.71 | CXCR3 (0.51) | PDE10AMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL453979 | 0.71 | CXCR3 (0.47) | MEN1KMT2ACXCR3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | PDE10A 1893/4885MEN1 4424/4885KMT2A 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.